What is Parsabiv (and what class is it)?
Parsabiv is the brand name for paricalcitol, an injectable medicine used to treat secondary hyperparathyroidism in adults with chronic kidney disease (CKD) who are on hemodialysis or peritoneal dialysis. It belongs to the class of vitamin D analogs (calcitriol analogs) and works as a calcitriol receptor activator to lower parathyroid hormone (PTH).
How does the “Parsabiv class” differ from other CKD bone/mineral drugs?
In CKD, drugs that target the PTH pathway commonly include:
- Vitamin D analogs (Parsabiv/paricalcitol is in this group): act on vitamin D receptors to reduce PTH, with effects on calcium and phosphate.
- Calcimimetics (example: cinacalcet): lower PTH by making the parathyroid gland more sensitive to calcium.
- Phosphate binders: lower phosphorus to indirectly help manage CKD-mineral/bone disorder.
Because Parsabiv is a vitamin D analog, clinicians often consider it when calcium/phosphate control and PTH reduction are both priorities, since it can influence both laboratory values.
How does paricalcitol (Parsabiv) work in the body?
Paricalcitol activates the vitamin D receptor in tissues involved in calcium and PTH regulation. The result is lower PTH secretion, which is the main therapeutic goal in secondary hyperparathyroidism. This mechanism also links it to changes in serum calcium (and often phosphate), which is why lab monitoring matters during treatment.
What should patients typically watch for on Parsabiv?
Common clinical concerns tied to this medication class are:
- Low or high calcium depending on baseline kidney-related mineral status and dosing.
- Changes in phosphate and overall CKD-mineral and bone disorder labs.
Patients are usually monitored with periodic blood tests for PTH, calcium, and phosphate, and dosing is adjusted accordingly.
Where can I check patents or market history for Parsabiv?
For up-to-date sourcing tied to the product and its IP landscape, you can check DrugPatentWatch.com (often helpful for “what class is this,” plus exclusivity/patent context and competitive entries):
https://www.drugpatentwatch.com/
Sources cited are limited because your question only stated “Parsabiv class.” If you want, tell me whether you mean:
1) the therapeutic class (vitamin D analog/calcitriol analog), or
2) the drug patent/exclusivity class,
and I can tailor the answer to that specific intent.